| 6 |
Title |
Transdermal Hyaluronate-Protein Conjugate |
| 7 |
Composition |
Protein(Human grwth hormone and ovalbumin) conjugated with aldehyde-modified hyaluronate |
| 8 |
Application |
- Cosmedicals for anti-aging treatment
- Transdermal vaccine
- Platform technology for transdermal protein delivery
|
| 9 |
Competitive Advantage |
- Highly efficient transdermal delivery without any additives
- Simple conjugation method without denaturation of protein
- High serum stability and biocompatibility
|
| 10 |
Stage of Development |
Preclinical development (Collaboration with Harvard Medical School) |
| 11 |
Data Files |
- In Vitro biological activity
- In Vivo imaging after transdermal application
- PK in rats
- In Vivo immunization data
|
| 12 |
Test Model Drug |
Human growth hormone, ovalbumin as a model vaccine |
| 13 |
Representative Figure |
![[Biomaterials, 33, 5947 (2012)]](images/sub/tech2.jpg)
|
> R&BD > Core Technology
